Pınar Sari YOLSEL, Kamil Serkan UZYOL, Özlem Ateş DURU, Muhammet Volkan BÜLBÜL, Semiha Mervenur EVREN, Özge ÇELİK
Journal of Experimental and Clinical Medicine - 2026;43(2):159-168
Colorectal cancer constitutes a considerable global health challenge due to its strong contribution to cancer-linked morbidity and mortality. Gut microbiota and their metabolites are increasingly recognized as modulators of tumor progression and the tumor microenvironment. This study examined the effects of extracellular metabolites from B. animalis subsp. animalis on human CRC cell lines (HCT-116 and HT-29) and on pathogenic bacteria (Escherichia coli and Staphylococcus aureus). Metabolite exposure produced dose-dependent inhibition of CRC cell viability, with IC?? values of 63.92 µL/mL for HCT-116 and 46.86 µL/mL for HT-29, while causing minimal cytotoxicity in non-tumorigenic HUVEC cells. Flow cytometry indicated a modest rise in late apoptotic populations, suggesting activation of apoptotic pathways without extensive cell death. Antimicrobial assays showed effective, time- and dose-dependent suppression of E. coli and S. aureus growth under aerobic and anaerobic conditions. These findings suggest B. animalis-derived metabolites exert direct anticancer effects and indirectly modulate the tumor microenvironment by inhibiting pathogenic bacterial colonization.
